Annual Net Income
-$15.79 M
-$1.17 M-7.97%
31 December 2023
Summary:
Entero Therapeutics annual net profit is currently -$15.79 million, with the most recent change of -$1.17 million (-7.97%) on 31 December 2023. During the last 3 years, it has risen by +$42.74 million (+73.02%). ENTO annual net income is now -166.35% below its all-time high of -$5.93 million, reached on 01 December 2015.ENTO Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$2.58 M
+$6.23 M+70.70%
01 September 2024
Summary:
Entero Therapeutics quarterly net profit is currently -$2.58 million, with the most recent change of +$6.23 million (+70.70%) on 01 September 2024. Over the past year, it has increased by +$1.52 million (+37.06%). ENTO quarterly net income is now -146.36% below its all-time high of $5.57 million, reached on 31 March 2024.ENTO Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$9.92 M
+$853.20 K+7.92%
01 September 2024
Summary:
Entero Therapeutics TTM net profit is currently -$9.92 million, with the most recent change of +$853.20 thousand (+7.92%) on 01 September 2024. Over the past year, it has increased by +$5.87 million (+37.18%). ENTO TTM net income is now -732.87% below its all-time high of -$1.19 million, reached on 01 March 2015.ENTO TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTO Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +37.1% | +37.2% |
| 3 y3 years | +73.0% | +76.9% | +83.0% |
| 5 y5 years | -4.1% | -101.4% | +34.6% |
ENTO Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -8.0% | +73.0% | -146.4% | +76.9% | -61.2% | +83.6% |
| 5 y | 5 years | -8.0% | +73.0% | -146.4% | +91.5% | -61.2% | +84.7% |
| alltime | all time | -166.3% | +73.0% | -146.4% | +91.5% | -732.9% | +84.7% |
Entero Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.58 M(-70.7%) | -$9.92 M(-7.9%) |
| June 2024 | - | -$8.81 M(-258.2%) | -$10.78 M(+75.0%) |
| Mar 2024 | - | $5.57 M(-235.8%) | -$6.16 M(-61.0%) |
| Dec 2023 | -$15.79 M(+8.0%) | -$4.10 M(+19.4%) | -$15.79 M(+0.7%) |
| Sept 2023 | - | -$3.43 M(-18.0%) | -$15.68 M(+99.6%) |
| June 2023 | - | -$4.19 M(+2.9%) | -$7.85 M(-13.4%) |
| Mar 2023 | - | -$4.07 M(+2.1%) | -$9.07 M(-38.0%) |
| Dec 2022 | -$14.63 M(-75.0%) | - | - |
| Dec 2022 | - | -$3.99 M(-190.8%) | -$14.63 M(-32.9%) |
| Sept 2022 | - | $4.39 M(-181.2%) | -$21.82 M(-61.5%) |
| June 2022 | - | -$5.41 M(-43.8%) | -$56.61 M(-6.4%) |
| Mar 2022 | - | -$9.63 M(-13.8%) | -$60.48 M(+3.3%) |
| Dec 2021 | -$58.54 M(+79.2%) | -$11.17 M(-63.2%) | -$58.54 M(-9.6%) |
| Sept 2021 | - | -$30.40 M(+227.6%) | -$64.77 M(+63.2%) |
| June 2021 | - | -$9.28 M(+20.7%) | -$39.68 M(+13.1%) |
| Mar 2021 | - | -$7.69 M(-55.8%) | -$35.10 M(+7.4%) |
| Dec 2020 | -$32.67 M(+115.3%) | -$17.40 M(+227.5%) | -$32.67 M(+97.4%) |
| Sept 2020 | - | -$5.31 M(+13.2%) | -$16.55 M(+7.3%) |
| June 2020 | - | -$4.70 M(-10.7%) | -$15.43 M(-2.2%) |
| Mar 2020 | - | -$5.26 M(+310.5%) | -$15.78 M(+4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$15.18 M(+12.1%) | -$1.28 M(-69.4%) | -$15.18 M(-15.3%) |
| Sept 2019 | - | -$4.19 M(-16.9%) | -$17.92 M(+9.9%) |
| June 2019 | - | -$5.04 M(+8.2%) | -$16.30 M(+11.9%) |
| Mar 2019 | - | -$4.66 M(+15.9%) | -$14.56 M(+7.6%) |
| Dec 2018 | -$13.53 M(+22.0%) | -$4.02 M(+56.3%) | -$13.53 M(+12.8%) |
| Sept 2018 | - | -$2.57 M(-22.3%) | -$11.99 M(-4.5%) |
| June 2018 | - | -$3.31 M(-8.9%) | -$12.56 M(+5.3%) |
| Mar 2018 | - | -$3.63 M(+46.4%) | -$11.92 M(+7.4%) |
| Dec 2017 | -$11.10 M(-24.0%) | -$2.48 M(-20.8%) | -$11.10 M(-22.1%) |
| Sept 2017 | - | -$3.13 M(+17.3%) | -$14.25 M(-0.4%) |
| June 2017 | - | -$2.67 M(-4.9%) | -$14.31 M(-7.1%) |
| Mar 2017 | - | -$2.81 M(-50.1%) | -$15.41 M(+5.6%) |
| Dec 2016 | -$14.59 M(+146.1%) | -$5.63 M(+76.1%) | -$14.59 M(+51.6%) |
| Sept 2016 | - | -$3.20 M(-15.2%) | -$9.63 M(+16.0%) |
| June 2016 | - | -$3.77 M(+89.4%) | -$8.30 M(+23.4%) |
| Mar 2016 | - | -$1.99 M(+198.9%) | -$6.73 M(+13.5%) |
| Dec 2015 | -$5.93 M | -$666.20 K(-64.4%) | -$5.93 M(+12.7%) |
| Sept 2015 | - | -$1.87 M(-14.8%) | -$5.26 M(+55.3%) |
| June 2015 | - | -$2.20 M(+84.6%) | -$3.39 M(+184.6%) |
| Mar 2015 | - | -$1.19 M | -$1.19 M |
FAQ
- What is Entero Therapeutics annual net profit?
- What is the all time high annual net income for Entero Therapeutics?
- What is Entero Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Entero Therapeutics?
- What is Entero Therapeutics quarterly net income year-on-year change?
- What is Entero Therapeutics TTM net profit?
- What is the all time high TTM net income for Entero Therapeutics?
- What is Entero Therapeutics TTM net income year-on-year change?
What is Entero Therapeutics annual net profit?
The current annual net income of ENTO is -$15.79 M
What is the all time high annual net income for Entero Therapeutics?
Entero Therapeutics all-time high annual net profit is -$5.93 M
What is Entero Therapeutics quarterly net profit?
The current quarterly net income of ENTO is -$2.58 M
What is the all time high quarterly net income for Entero Therapeutics?
Entero Therapeutics all-time high quarterly net profit is $5.57 M
What is Entero Therapeutics quarterly net income year-on-year change?
Over the past year, ENTO quarterly net profit has changed by +$1.52 M (+37.06%)
What is Entero Therapeutics TTM net profit?
The current TTM net income of ENTO is -$9.92 M
What is the all time high TTM net income for Entero Therapeutics?
Entero Therapeutics all-time high TTM net profit is -$1.19 M
What is Entero Therapeutics TTM net income year-on-year change?
Over the past year, ENTO TTM net profit has changed by +$5.87 M (+37.18%)